Tehran University of Medical Sciences
Office of Vice-Chancellor for Global Strategies & International Affairs
International Human Capacity Development (IHCD)
Code : 9345-351861      Publish Date : Tuesday, October 4, 2016 Visit : 1343

Intl. Congress form | International Congress Report | International Congress Report For Faculty | European Breast Cancer Conference (EBCC10)

European Breast Cancer Conference (EBCC10)
The report of European Breast Cancer Conference (EBCC10) by Dr. Gholam Ali Kardar
Application Code :
306-0116-0050
 
Created Date : Saturday, April 2, 2016 13:21:54Update Date : Monday, May 23, 2016 15:44:27
IP Address : 192.168.89.5Submit Date : Monday, May 23, 2016 15:45:01Email : gakardar@tums.ac.ir
Personal Information
Name : Gholam Ali
Surname : Kardar
School/Research center : Immunology, Asthma and Allergy Research Institute (IAARI)
If you choose other, please name your Research center :  
Position : Assistant professor
Tel : +98-21-61472147
Information of Congress
Title of the Congress : European Breast Cancer Conference (EBCC10)
Title of your Abstract : The effect of VEGF peptide vaccine on inhibition of metastasis in mice breast cancer model
Destination Country : Netherlands
From : Wednesday, March 9, 2016
To : Friday, March 11, 2016
Abstract(Please copy/paste the abstract send to the congress) : Introduction: Breast cancer is the most prevalent cancer in the women that cancer cells metastasis to different tissues and impair the function of them.
Cancer cells for growth and development secret some metastatic factors that one of them is vascular endothelial growth factor (VEGF). Already peptide based vaccines are one of the immunotherapy approaches. In this study a peptide based vaccine designed and used for induction of immune system against of VEGF molecule.
Material and Methods: By bioinformatics, a part of the VEGF molecule was selected as a peptide based vaccine and conjugated with the KLH carrier. BALB/c mice divided into three groups that one group received peptide vaccine and then 4T1 breast cancer model was created, the second group were only 4T1 breast cancer model and third group were negative control. The mice serums were taken at intervals and the titration of serum IgG against VEGF was measured using ELISA. The weights of the mice in all of the groups as well as the primary tumor volume in vaccinated and
tumoral group were measured respectively.
Results: The titer of anti-VEGF IgG had significantly increased in
vaccinated group compared to tumoral group. Tumor growth in the
vaccinated group compared to tumoral group showed the dramatic
decrease. As well as the survival rate in the vaccinated group was more than the tumoral group and less than the negative control group.
Conclusion: The results of this research show that the designed peptide based vaccine to be able to inhibit the growth and spread of tumoral cells in murine model.
Keywords of your Abstract : Endothelial Growth Factor (VEGF), Peptide based vaccine, Metastasis
Acceptance Letter : http://gsia.tums.ac.ir/images/UserFiles/29473/Forms/306/emza_nafar_aval.pdf
The presentation : Poster
The Cover of Abstract book : http://gsia.tums.ac.ir/images/UserFiles/29473/Forms/306/EBCC10_Abstract_book_1.pdf
Published abstract in the abstract book with the related code : http://gsia.tums.ac.ir/images/UserFiles/29473/Forms/306/abstract page_1.pdf
Where has your abstract been indexed? : Scoups
If you choose other, please name :  
The Congress Reporting Form
How many volunteers were present at the Congress? : 6000
Delegates from which countries presented in the congress? : USA-UK-Netherlands-Italy-Canada
Were the delegates of any other organizations present in the congress? : No
If yes, please write the names of the organizations in the box :  
What were the responses to your talking points? Were specific questions or concerns raised? : In Congress I presented my student thesis work, Miss Fazeli, and some participates would liked our study and interested for collaboration like Dr. Alexander М Scherbakov from Russia.
If you met staff members, please list their full names & positions. : Dr. Alexander М Scherbakov;
Laboratory of Clinical Biochemistry, Institute of Clinical Oncology, N.N. Blokhin Cancer Research Centre, Moscow, Russia
Dr. John Haanen, NKI, Netherland
Dr. . János Szebeni, Seriscience, Budapest
 
Please inform us if there are any follow up actions we need to talk with the members of the congress : No follow up action needs............................................................................................................... ............................................................................................................................................................................................................................................
mamnoon
Your experiences about the travel processes(Providing ticket, accommodation,...) : in inter europ country, trip is very cheap
Please give a briefing of your own observations and outcomes of the congress: : Biannually, In European Breast Cancer Conference (EBCC10) the basic and clinical scientists from around the world convene. in this event researchers share their findings and experiences in the field of prevention and treatment of breast cancer. This congress was held in Amsterdam, Bicycles city, in March 9-11. I went before Congress to Amsterdam and then get familiar with the city. On 7th March I visited of Immunology section, The Netherlands Cancer Institute (NKI). NKI is one of the leading centers in the field of cancer research and treatment. In Congress I presented my student thesis work, Miss Fazeli, and some participates would liked our study and interested for collaboration like Dr. Alexander М Scherbakov from Russia.
One of the major topics of this conference was discussion about personalized medicine and translational medicine in breast cancer treatment. And this exactly is our group interesting. Also the importance of life style and nutrition in both prevention and treatment of breast cancer were confirmed.
After conference, I went to the Budapest and along with Dr. Ghaffari visited of Semmelweis University and also SeroScience and meet it’s CEO, Dr. János Szebeni. We talked and agreed about some common projects.